参考文献
(在框内滑动手指即可浏览)
[1] Elisei R,Tacito A,Ramone T,et al.Twenty-five years experience on RET genetic screening on hereditary MTC: An update on the prevalence of germline RET mutations[J].Genes (Basel),2019,10(9):698.
[2] Raue F,Frank-Raue K,Frank-Raue K.Genotype-phenotype correlation in multiple endocrine neoplasia type 2[J].Clinics (Sao Paulo),2012,67(suppl):69-75.
[3] Verga U,Fugazzola L,Cambiaghi S,et al.Frequent association between MEN 2A and cutaneous lichen amyloidosis[J].Clin Endocrinol (Oxf),2003,59(2):156-161.
[4] Amy E,Rothberg,Victoria M,et al.Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis[J].Thyroid,2009,19:651-655.
[5] Decker RA,Peacock ML,Peacock ML.Occurrence of MEN 2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene[J].J Pediatr Surg,1998,33(2):207-214.
[6] Mulligan LM,Ponder BA. Genetic basis of endocrine disease: multiple endocrine neoplasia type 2[J].J Clin Endocrinol Metab,1995,80:1989-1995.
[7] Smith DP,Houghton C,Ponder BA.Germline mutation of RET codon 883 in two cases of de novo MEN 2B[J].Oncogene,1997,15(10):1213-1217.
[8] Iñiguez-Ariza NM,Jasim S,Ryder MM,et al.Foundation one genomic interrogation of thyroid cancers in patients with metastatic disease requiring systemic therapy[J].J Clin Endocrinol Metab,2020,105(7):246.
[9] Machens A,Gimm O,Hinze R,et al.Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties[J].J Clin Endocrinol Metab,2001,86(3):1104-1109.
[10] Frohnauer MK,Decker RA,Decker RA.Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated?[J].Surgery,2000,128(6):1052-1057.
[11] Garcés Visier C,Espinoza Vega M,Guillén Redondo P,et al.Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A in children: a single centre experience[J].J Pediatr Endocrinol Metab,2019,32(8):889-893.
[12] Castinetti F,Waguespack SG,Machens A,et al.Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study[J].Lancet Diabetes Endocrinol,2019,7(3):213-220.
[13] Chambon G,Alovisetti C,Idouxlouche C,et al.The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients[J].J Clin Endocrinol Metab,2011,96(1):75-81.
[14] 殷德涛,张高朋,李红强,等.甲状腺结节患者常规行血清降钙素检查对早期发现甲状腺髓样癌的临床价值[J].中国普通外科杂志,2018,27(5):541-546.
[15] 中国抗癌协会甲状腺癌专业委员会.甲状腺癌血清标志物临床应用专家共识(2017版)[J].中国肿瘤临床,2018,45(1):7-13.
[16] Dora JM,Canalli MH,Capp C,et al.Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature[J].Thyroid,2008,18(8):895-899.
[17] Chen H,Sippel RS,Odorisio MS,et al.The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer[J].Pancreas,2010,39(6):775-783.
[18] 中国医师协会外科医师分会甲状腺外科医师委员会,中国研究型医院学会甲状腺疾病专业委员会,中国医学装备协会外科装备分会甲状腺外科装备委员会. 超声引导下甲状腺结节细针穿刺活检专家共识及操作指南(2018版)[J].中国实用外科杂志,2018,38(3):241-244.
[19] Dyhdalo KS,Chute DJ,Chute DJ.Barriers to the recognition of medullary thyroid carcinoma on FNA: Implications relevant to the new American Thyroid Association guidelines[J].Cancer Cytopathol,2018,126(6):397-405.
[20] Liu MJ,Liu ZF,Hou YY,et al.Ultrasonographic characteristics of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma[J].Oncotarget,2017,8(16):27520-27528.
[21] Jiang J,Yang Z,Zhang Y,et al.Clinical value of [(18)F]FDG-PET-CT in the detection of metastatic medullary thyroid cancer[J].Clin Imaging,2014,38(6):797-801.
[22] Essig GF,Porter K,Schneider D,et al.Multifocality in sporadic medullary thyroid carcinoma: an international multicenter study[J].Thyroid,2016,26(11):1563-1572.
[23] 刘溦薇,邓先兆,樊友本,等.散发性甲状腺髓样癌规范与非规范手术的效果观察[J].中国普外基础与临床杂志,2014,21(11):1408-1412.
[24] Weber T,Schilling T,Frank-Raue K,et al.Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas[J].Surgery,2001,130(6):1044-1049.
[25] Zhang L,Wei WJ,Ji QH,et al.Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients[J].J Clin Endocrinol Metab,2012,97(4):1250-1257.
[26] 高云飞,邓维叶,陈艳峰,等.甲状腺髓样癌预后相关因素分析(附118例报告)[J].中国实用外科杂志,2015,35(9):996-1000.
[27] Deftos LJ,Stein MF.Radioiodine as an adjunct to the surgical treatment of medullary thyroid carcinoma[J].J Clin Endocrinol Metab,1980,50(5):967-968.
[28] Wells SAJr,Robinson BG,Gagel RF,et al.Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial[J].J Clin Oncol,2012,30(2):134-141.
[29] Tappenden P,Carroll C,Hamilton J,et al.Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model[J].Health Technol Assess,2019,23(8):1-144.
[30] Schlumberger M,Jarzab B,Cabanillas ME,et al.A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer[J].Clin Cancer Res,2016,22(1):44-53.
[31] Yongkun S,Feng D,Ming G,et al.Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer[J].Thyroid,2018,28(11): 1455-1461.
[32] Chen J,Ji Q,Bai C,et al.Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: A multicenter, open-label, Phase II trial[J].Thyroid. 2020 Apr 6. doi: 10.1089/thy.2019.0453. Online ahead of print.
[33] Rowell NP.The role of external beam radiotherapy in the management of medullary carcinoma of the thyroid: A systematic review[J].Radiother Oncol,2019,136(2019):113-120.
[34] Capp C,Wajner SM,Siqueira DR,et al.Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma[J].Thyroid,2010,20(8):863-871.
[35] Shi X,Yu PC,Lei BW,et al.Association between programmed death-ligand 1 expression and clinicopathological characteristics, structural recurrence, and biochemical recurrence/persistent disease in medullary thyroid carcinoma[J].Thyroid,2019,29(9):1269-1278.
[36] Sherman SI,Clary DO,Elisei R,et al.Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer[J].Cancer,2016,122(24):3856-3864.
[37] Lam ET,Ringel MD,Kloos RT,et al.Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer[J].J Clin Oncol,2010,28(14):2323-2330.
[38] Ito Y,Onoda N,Ito KI,et al.Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma[J].Thyroid,2017,27(9):1142-1148.
[39] Subbiah V,Gainor JF,Rahal R,et al.Precision targeted therapy with BLU-667 for RET-driven cancers[J].Cancer Discov,2018,8(7):836-849.
[40] Subbiah V,Velcheti V,Tuch BB,et al. Selective RET kinase inhibition for patients with RET-altered cancers[J].Ann Oncol,2018,29(8):1869-1876.
[41] Marchand L,Nozieres C,Walter T,et al.Combination chemotherapy with 5-fluorouracil and dacarbazine in advanced medullary thyroid cancer, a possible alternative?[J].Acta Oncol,2016,55(8):1064-1066.
[42] Nocera M,Baudin E,Pellegriti G,et al.Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine[J].Br J Cancer,2000,83(6):715-718.
[43] Iten F,Muller B,Schindler C,et al.Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial[J].Clin Cancer Res,2007,13(22):6696-6702.
[44] Maiza JC,Grunenwald S,Otal P,et al.Use of 131 I-MIBG therapy in MIBG-positive metastatic medullary thyroid carcinoma[J].Thyroid,2012,22(6):654-655.
[45] Pasieka JL,Mcewan AJB,Rorstad O.The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms[J].Surgery,2004,136(6):1218-1226.
[46] Satapathy S,Mittal BR,Sood A,et al.Efficacy and safety of concomitant 177 Lu-DOTATATE and low- dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience[J].Nucl Med Commun,2020,41(7):629-635.
[47] Carlotta P,Chiara G,Elisa G,et al.Management strategies for aggressive Cushing's syndrome: from macroadenomas to ectopics[J].J Oncol,2012,2012:685213.
[48] Tuttle RM,Ganly I.Risk stratification in medullary thyroid cancer: Moving beyond static anatomic staging[J].Oral Oncol,2013,49(7):695-701.
[49] Bihan H,Becker KL,Snider RH,et al.Calcitonin precursor levels in human medullary thyroid carcinoma[J].Thyroid,2003,13(8):819-822.
[50] Walter MA,Meier C,Radimerski T,et al.Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer[J].Cancer,2009,116(1):31-40.
[51] Cupisti K,Wolf A,Raffel A,et al.Long-term clinical and biochemical follow-up in medullary thyroid carcinoma[J].Ann Surg,2007,246(5):815-821.
[52] Miyauchi A,Onishi T,Morimoto S,et al.Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma[J].Ann Surg,1984,199(4):461-466.
[53] Laure Giraudet A,Al Ghulzan A,Auperin A,et al.Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times[J].Eur J Endocrinol,2008,158(2):239.
[54] Kukulska A,Krajewska J,Kolosza Z,et al.The role of postoperative adjuvant radiotherapy in the local control in medullary thyroid carcinoma[J].Endocr Connect,2020,9(1):1-8.